glp 1 drug class America's Poison Centers List of GLP-1 Receptor Agonists

Distribution Channel Analysis The retail pharmacy segment was the largest distribution channel in the global anti-obesity drugs market, commanding a significant share of over 56.7% in 2024

GLP-1 receptor agonists obesity drugs market captured the largest revenue share of 81% in 2024 within North America, driven by high obesity prevalence, early drug approvals, and robust healthcare infrastructure

According to an article published in Diabetes Therapy , Co-infusion of GLP-1 and GIP has a synergistic effect, resulting in significantly increased insulin response and glucagonostatic (glucagon stabilizing) response, compared with administration of either hormone alone. In other words, combining GLP-1 and GIP receptor agonists in a single drug appears to have a greater impact on blood sugar control than GLP-1 used alone

[DOI] [PubMed] [Google Scholar] 45.Baetta R., Corsini A

The safety and effectiveness of recently developed and future expected obesity drugs combined with other treatment modalities (such as bariatric surgery or drastic lifestyle changes) need to be further investigated